Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids

Journal of Clinical Lipidology

Volumn 7, Issue 3 SUPPL., 2013, Pages S1-

  Cohen, Jonathan C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Familial hypercholesterolemia; Genetics; LDL cholesterol; PCSK9; Sequencing

Indexed keywords

ADAPTOR PROTEIN; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SUBTILISIN;

AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; CODON; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LOSS OF FUNCTION MUTATION; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS (TOPIC); MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK REDUCTION;

EID: 84877578553     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.03.005     Document Type: Article

References (27)

1. P. Linsel-Nitschke, A. Götz, J. Erdmann Wellcome Trust Case Control Consortium (WTCCC); Cardiogenics Consortium Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease - a Mendelian Randomisation study PLoS One 3 2008 e2986
2. M. Varret, M. Abifadel, J.P. Rabes, and C. Boileau Genetic heterogeneity of autosomal dominant hypercholesterolemia Clin Genet 73 2008 1 13
3. J.E. Eichner, S.T. Dunn, G. Perveen, D.M. Thompson, K.E. Stewart, and B.C. Stroehla Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review Am J Epidemiol 155 2002 487 495
4. T.M. Teslovich, K. Musunuru, and A.V. Smith Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 2010 707 713
5. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
6. D. Marks, M. Thorogood, H.A. Neil, and S.E. Humphries A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia Atherosclerosis 168 2003 1 14
7. P.N. Hopkins, P.P. Toth, C.M. Ballantyne, D.J. Rader National Lipid Association Expert Panel on Familial Hypercholesterolemia Familial hypercholesterolemias: prevalence, genetics, diagnosis, and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia J Clin Lipidol 5 3 Suppl 2011 S9 S17
8. A.K. Khachadurian Prospects for the prenatal diagnosis of familial hypercholesterolemia J Med Liban 26 1973 325 329
9. T.L. Innerarity, K.H. Weisgraber, and K.S. Arnold Familial defective apolipoprotein B-100: low-density lipoproteins with abnormal receptor binding Proc Natl Acad Sci USA 84 1987 6919 6923
10. M. Abifadel, M. Varret, and J.P. Rabés Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156
11. M.H. Lee, K. Lu, and S.B. Patel Genetic basis of sitosterolemia Curr Opin Lipidol 12 2001 141 149
12. J.C. Cohen, M. Kimmel, A. Polanski, and H.H. Hobbs Molecular mechanisms of autosomal recessive hypercholesterolemia Curr Opin Lipidol 14 2003 121 127
13. R.C. Bauer, I.M. Stylianou, and D.J. Rader Functional validation of new pathways in lipoprotein metabolism identified by human genetics Curr Opin Lipidol 22 2011 123 128
14. C.J. Willer, and K.L. Mohlke Finding genes and variants for lipid levels after genome-wide association analysis Curr Opin Lipidol 23 2012 98 103
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
16. N.K. Kapur, D. Ashen, and R.S. Blumenthal High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease Vasc Health Risk Manag 4 2008 39 57
17. B.F. Voight, G.M. Peloso, and M. Orho-Melander Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study Lancet 380 2012 572 580
18. J. Cohen, A. Pertsemlidis, I.K. Kotowski, R. Graham, C.K. Garcia, and H.H. Hobbs Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 Nat Genet 37 2005 161 165
19. I.K. Kotowski, A. Pertsemlidis, and A. Luke A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol Am J Hum Genet 78 2006 410 422
20. R. McPherson, and N. Kavaslar Statins for primary prevention of coronary artery disease Lancet 369 2007 1078 1079
21. M. Benn, B.G. Nordestgaard, P. Grande, P. Schnohr, and A. Tybaerg-Hansen PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analysis J Am Coll Cardiol 55 2010 2833 2842
22. C.J. Willer, S. Sanna, and A.U. Jackson Newly identified loci that influence lipid concentrations and risk of coronary artery disease Nat Genet 40 2008 161 169
23. J. Rios, E. Stein, J. Shendure, H.H. Hobbs, and J.C. Cohen Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia Hum Mol Genet 19 2010 4313 4318
24. A.J. Hooper, A.D. Marais, D.M. Tanyanyiwa, and J.R. Burnett The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population Atherosclerosis 193 2007 445 448
25. E.A. Stein, S. Mellis, and G.D. Yancopoulos Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 2012 1108 1118
26. G. Schonfeld, X. Lin, and P. Yue Familial hypobetalipoproteinemia: genetics and metabolism Cell Mol Life Sci 62 2005 1372 1378
27. K. Musunuru, J.P. Pirruccello, and R. Do Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia N Engl J Med 363 2010 2220 2227